Melphalan and Prednisone (MP) versus Vincristine, BCNU, Adriamycin, Melphalan and Dexamethasone (VBAM Dex) Induction Chemotherapy and Interferon Maintenance Treatment in Multiple Myeloma

Peest, D.; Deicher, H.; Coldewey, R.; Leo, Regine; Bartl, Reiner; Bartels, H.; Braun, Hans J.; Broen, I.-M. von; Fischer, J; Gramatzki, Martin; Hein, Reinhard; Henke, Rolf‐Peter; Hoffmann, Lutz; Kreuser, Ernst-Dietrich; Maier, Wolfgang D.; Meier, Christian; Oertel, Joachim; Planker, M.; Reinhold, H.M.; Schäfer, E.; Schumacher, Eva; K, Schumacher; Selbach, Johannes; Stennes, Mark; Stenzinger, W; Tirier, C.; Wagner, Helmut; Weh, Hans-Josef; Wysk, J

doi:10.1159/000216820

Cited by 24 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conflicting results are reported also from studies using IFN-a in maintenance of myeloma. Some studies show prolongation of disease-free survival or of the plateau phase (9,33,34) whereas others show no effect of IFN-a (35,36). Significant differences exist in the design of these studies; in the Italian study (e.g.…”

Section: Discussionmentioning

confidence: 99%

Maintenance therapy with interferon‐α (IFN‐α) versus IFN‐α plus chemotherapy in multiple myeloma (MM)

Zervas¹,

Pouli

Perifanis³

et al. 1996

European J of Haematology

View full text Add to dashboard Cite

Results of studies using IFN‐α treatment for maintaining remission and prolonging survival in multiple myeloma (MM) are in conflict and trials seeking optimum use for this biological response modifier are continuing. Between 1989 and 1993 a prospective randomized multicentre trial was undertaken to evaluate the role of the combination of IFN‐α with chemotherapy (CT) in maintenance treatment of MM. For remission induction, in patients 65 yr or younger, we used VAD (group A) and for the remaining Melphalan and Prednisone (MP) (group B). For maintenance, patients were randomized to receive IFN‐α 3times106 i.u. s.c. t.i.w. (group I) or alternating monthly cycles of IFN‐α and CT. The CT cycles were also alternated (VAD, MP, CP) in an effort to prevent the development of multidrug resistance. Median survival of the two maintenance groups from randomization (36 months for group I and 31 months for group II, p=0.3) as well as response duration (13 months in group I and 15 months in group II, p=0.95) were similar. Toxicities were more pronounced both with VAD induction and in the combination maintenance arm. The addition of chemotherapy to the IFN maintenance regimen in MM did not have an advantage over IFN alone.

show abstract

Section: Discussionmentioning

confidence: 99%